Cat No.: 31101 Other Names: THBS2
Introduction
Thrombospondin-2 (TSP-2) is a 150 kDa calcium-binding protein. TSP-2 inhibits angiogenesis through direct effect on endothelial
cell migration, proliferation, survival and apoptosis. It is a potential risk factor in heart disease.
Principle of the Assay
This assay is a quantitative sandwich ELISA. The immunoplate is pre-coated with a monoclonal antibody specific for human TSP-2. Standards and samples are pipetted into the wells and any human TSP-2 present is bound by the immobilized antibody. After
washing away any unbound substances, a biotin labelled polyclonal antibody specific for human TSP-2 is added to the wells. After
wash step to remove any unbound reagents, streptavidin-HRP conjugate (STP-HRP) is added. After the last wash step, an HRP
substrate solution is added and colour develops in proportion to the amount of human TSP-2 bound initially. The assay is stopped
and the optical density of the wells determined using a microplate reader. Since the increases in absorbance are directly
proportional to the amount of captured human TSP-2, the unknown sample concentration can be interpolated from a reference
curve included in each assay.
Assay Performance
A. Typical representation of standard curve
The following standard curve is provided for demonstration only. A standard curve should be generated for each set of sample
assay.
Human TSP-2 (ng/mL) | Absorbance (450 nm) | Blanked Absorbance |
0 | 0.094 | 0 |
0.156 | 0.133 | 0.039 |
0.312 | 0.187 | 0.093 |
0.625 | 0.293 | 0.199 |
1.25 | 0.474 | 0.38 |
2.5 | 0.812 | 0.718 |
5 | 1.317 | 1.223 |
10 | 2.096 | 2.002 |
B. Sensitivity
The lowest insulin level that can be measured by this assay is 0.156 ng/mL.
C. Precision
Intra-assay Precision (Precision within an assay) C.V.<4.6%.
Inter-assay Precision (Precision between assays) C.V.<7.2%.
Publications Citing This Product
1. Lee CH, Seto WK, Lui DT, Fong CH, Wan HY, Cheung CY, Chow WS, Woo YC, Yuen MF, Xu A, Lam KS. Circulating
thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care. 2021 Sep 1;44(9):2089-97.